Sec Form 3 Filing - Drape Eric @ TEVA PHARMACEUTICAL INDUSTRIES LTD - 2019-10-02

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Drape Eric 2. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Executive VP Global Operations (Last) (First) (Middle) C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 5 BASEL STREET 3. Date of Earliest Transaction (MM/DD/YY) 10/02/2019 (Street) PETACH TIKVA, L34951033 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares ( 1 ) 17,195 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (right to buy) $ 40.15 ( 2 ) 12/09/2023 Ordinary Shares ( 1 ) 25,005 D Stock Options (right to buy) $ 48.76 ( 3 ) 03/11/2024 Ordinary Shares ( 1 ) 15,002 D Stock Options (right to buy) $ 57.35 ( 4 ) 02/11/2025 Ordinary Shares ( 1 ) 54,623 D Stock Options (right to buy) $ 55.75 ( 5 ) 02/11/2026 Ordinary Shares ( 1 ) 54,950 D Stock Options (right to buy) $ 34.9 ( 6 ) 02/14/2027 Ordinary Shares ( 1 ) 62,364 D Stock Options (right to buy) $ 16.99 ( 7 ) 09/18/2027 Ordinary Shares ( 1 ) 33,339 D Stock Options (right to buy) $ 18.61 ( 8 ) 02/08/2028 Ordinary Shares ( 1 ) 50,231 D Restricted Share Units ( 10 ) ( 9 ) ( 9 ) Ordinary Shares ( 1 ) 7,852 D Restricted Share Units ( 10 ) ( 11 ) ( 11 ) Ordinary Shares ( 1 ) 19,702 D Restricted Share Units ( 10 ) ( 12 ) ( 12 ) Ordinary Shares ( 1 ) 35,820 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Drape Eric C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA, L34951033 Executive VP Global Operations Signatures /s/ Dov Bergwerk, as attorney-in-fact for Eric Drape 10/15/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. ( 2 )Stock options were granted on December 9, 2013, with 8,335 having vested on each of December 9, 2015, December 9, 2016 and December 9, 2017. ( 3 )Stock options were granted on March 12, 2014, with 5,000 having vested on each of March 12, 2015 and March 12, 2016 and 5,002 having vested on March 12, 2017. ( 4 )Stock options were granted on February 12, 2015, with 18,207 having vested on each of February 12, 2017 and February 12, 2018 and 18,209 on February 12, 2019. ( 5 )Stock options were granted on February 12, 2016, with 18,316 having vested on each of February 12, 2018 and February 12, 2019 and 18,318 vesting on February 12, 2020. ( 6 )Stock options were granted on February 14, 2017, with 20,788 having vested on February 14, 2019, and 20,788 vesting on each of February 14, 2020 and February 14, 2021. ( 7 )Stock options were granted on September 18, 2017 and vested on September 18, 2019. ( 8 )Stock options were granted on February 9, 2018, with 16,743 vesting on each of February 9, 2020 and February 9, 2021 and 16,745 vesting on February 9, 2022. ( 9 )Restricted share un its were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2020 and February 14, 2021. ( 10 )Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. ( 11 )Restricted share units were granted on February 9, 2018, with 6,567 vesting on each of February 9, 2020 and February 9, 2021 and 6,568 vesting on February 9, 2022. ( 12 )Restricted share units were granted on March 4, 2019, with 11,940 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.